Nalaganje...
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, ve...
Shranjeno v:
| izdano v: | Pharmacoecon Open |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710317/ https://ncbi.nlm.nih.gov/pubmed/30680676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-018-0115-y |
| Oznake: |
Označite
Brez oznak, prvi označite!
|